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Background: During tumor formation and expansion, increasing glucose metabolism is necessary for unrestricted
growth of tumor cells. Expression of key glycolytic enzyme alpha-enolase (ENO1) is controversial and its modulatory
mechanisms are still unclear in non-small cell lung cancer (NSCLC).
Methods: The expression of ENO1 was examined in NSCLC and non-cancerous lung tissues, NSCLC cell lines, and
immortalized human bronchial epithelial cell (HBE) by quantitative real-time reverse transcription PCR (qRT-PCR),
immunohistochemistry, and Western blot, respectively. The effects and modulatory mechanisms of ENO1 on cell
glycolysis, growth, migration, invasion, and in vivo tumorigenesis and metastasis in nude mice were also analyzed.
Results: ENO1 expression was increased in NSCLC tissues in comparison to non-cancerous lung tissues. Similarly,
NSCLC cell lines A549 and SPCA-1 also express higher ENO1 than HBE cell line in both mRNA and protein levels.
Overexpressed ENO1 significantly elevated NSCLC cell glycolysis, proliferation, clone formation, migration, and
invasion in vitro, as well as tumorigenesis and metastasis in vivo by regulating the expression of glycolysis, cell
cycle, and epithelial-mesenchymal transition (EMT)-associated genes. Conversely, ENO1 knockdown reversed these
effects. More importantly, our further study revealed that stably upregulated ENO1 activated FAK/PI3K/AKT and
its downstream signals to regulate the glycolysis, cell cycle, and EMT-associated genes.
Conclusion: This study showed that ENO1 is responsible for NSCLC proliferation and metastasis; thus, ENO1 might
serve as a potential molecular therapeutic target for NSCLC treatment.
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Lung cancer arises from the bronchial mucosal epithelium
and it is the leading cause of cancer mortality worldwide.
Non-small cell lung cancer (NSCLC) is the most commonly
diagnosed type of lung cancer, accounting for approxi-
mately 85% of all cases. Although the continuous progress
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unless otherwise stated.radiation therapy [1-3], prognoses have not significant im-
proved. In recent years, molecular targeted therapy [4,5]
has become the most prevalent approach. Therefore, the
understanding of the molecular alterations in NSCLC and
their pathways is significant for molecular targeted therapy.
During tumor formation and expansion, increasing glu-
cose metabolism is necessary for the unrestricted growth
of tumor cells [6]. Distributed in a variety of tissues, α-
enolase (ENO1) was originally described as an enzyme re-
sponsible for the glycolytic pathway [7]. In addition to its
glycolytic function, accumulating evidence has demon-
strated that ENO1 is a multifunctional protein involved in
several biological and pathophysiological processes de-
pending on its cellular localization [8]. The molecularis an Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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cytoplasm and considered as an oncogene in tumor
pathogenesis. However, another transcript of ENO1 can
be translated into a 37-kDa c-Myc promoter-binding pro-
tein (MBP-1), which represses transcription and is local-
ized in the nucleus [9-11].
Overexpression of ENO1 has been previously demon-
strated in several types of tumors including NSCLC [12].
However, investigators have reported conflicting results.
Some researchers have shown that the expression of
ENO1 was upregulated in NSCLC tissues and was associ-
ated with poorer clinical outcomes [13,14]. On the contrary,
Chang Y.S. et al. demonstrated that the levels of ENO1
protein were significantly decreased in NSCLC [15] and
overexpression of ENO1 inhibited epithelial-mesenchymal
transition (EMT) in the A549 cell line [16]. Therefore, nei-
ther expression nor the functional mechanisms of ENO1
in NSCLC have been clearly established.
In order to further validate the role of ENO1 and its
molecular basis in NSCLC, we analyzed the expression
of ENO1 in human NSCLC tissues and cell lines, as well
as its effects on cell glycolysis, growth, migration, andFigure 1 ENO1 is highly expressed in NSCLC. (A) The expression of ENO
quantitative RT-PCR. Data show the mean ± SD of three independent expe
non-cancerous lung specimens was analyzed by immunohistochemistry. a,
in non-cancerous lung tissues. (C) Immunofluorescence staining of ENO1 in
showing the expression of ENO1 mRNA and protein in two NSCLC cell line
show the mean ± SD of three independent experiments (*P < 0.05). β-Actininvasion in vitro and tumorigenicity and metastasis in vivo.
Our study showed that ENO1 is overexpressed in NSCLC
tissues, and upregulated ENO1 promotes cell glycolysis,
proliferation, migration, invasion, and tumorigenicity via
the FAK/PI3K/AKT pathway. This is the first report of the
molecular mechanisms of ENO1 in NSCLC, even more in-
depth than our previous report of ENO1 in glioma [17].
Results
ENO1 is highly expressed in NSCLC
Quantitative real-time reverse transcription PCR (qRT-
PCR) was used to measure the expression of ENO1
mRNA in 26 fresh primary NSCLC tissues (T), their
corresponding para-cancer lung tissues (P), and their
corresponding non-cancerous lung tissues (N). The
ENO1 mRNA expression level was increased in NSCLC
tissues in comparison to non-cancerous lung tissues (P <
0.05) (Figure 1A). The expression levels and subcellular
localization of ENO1 protein in 55 paraffin-embedded
primary NSCLC specimens and 17 paraffin-embedded
non-cancerous lung specimens were measured by im-
munohistochemical staining (Figure 1B). Expression of1 mRNA in NSCLC (T) and control tissues (P, N) was analyzed by
riments (*P < 0.05). (B) The expression of ENO1 protein in NSCLC and
b) Staining of ENO1 in primary NSCLC tissues. c, d) Staining of ENO1
A549 and SPCA-1 cells. (D) Quantitative RT-PCR and Western blot
s and immortalized normal bronchial epithelial cell line (HBE). Bars
served as protein loading control.
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observed in NSCLC tissue, but as ENO1 is only known
to localize in the cytoplasm, only this specific staining
was evaluated. ENO1 protein was highly expressed in
NSCLC tissues compared to non-cancerous lung sam-
ples (P = 0.019) (Table 1). Further, ENO1 was observed
to express in the cytoplasm but not in the nucleus in
NSCLC A549 and SPCA-1 cells by immunofluorescence
assay (Figure 1C), and its upregulated expression levels
in mRNA and protein were also found in both two cells
compared to immortalized human bronchial epithelial
cell line HBE (Figure 1D).
Stable ENO1-overexpressed and ENO1-suppressed NSCLC
cells as well as transient ENO1-suppressed NSCLC cells
were constructed
Since ENO1 expression is higher in SPCA-1 than in
A549 (Figure 1D), we firstly used lentivirus-mediated full-
length ENO1-GFP (ENO1) to constitutively overexpress
ENO1 in A549 cells in order to assess its role in NSCLC.
The result showed that ENO1 expression was obviously
upregulated in A549-ENO1 cells compared to its control
PLV-Ctr cells, and the expression of MBP-1 was not ob-
served (Figure 2A). Further, three lentiviral short hairpin
RNA (shRNA) vectors were used to specifically and stably
knock down the expression of ENO1 in the SPCA-1 cell
line, and the expression levels of ENO1 and MBP-1 were
determined by qRT-PCR and Western blot. The result
indicated that ENO1 expression was obviously down-
regulated in shENO1-B and shENO1-C cells compared
to their respective control PLV-scrambled control shRNA
(shCtr) cells (Figure 2B). Similarly, the expression of MBP-
1 was not observed in SPCA-1 cells (Figure 2B). To further
evaluate the functional significance of ENO1 on NSCLC,
small-interfering RNA (siRNA) was used to transiently
silence ENO1 in A549 and SPCA-1 cells, and the expres-
sion of ENO1 were validated by qRT-PCR and Western
blot (Figure 2C).
ENO1 regulates the glycolysis in NSCLC cells
To assess the glycolysis changes triggered by ENO1, we
used Western blot to detect the expression of lactate de-
hydrogenase A (LDHA) in ENO1-overexpressed A549 cells
and ENO1-suppressed SPCA-1 cells. We found that the
protein level of LDHA was markedly increased in ENO1-Table 1 Upregulation of ENO1 protein in NSCLC
specimens compared to non-cancerous lung specimens





NSCLC 55 34 21 0.019
Normal 17 5 12
Chi-square test.overexpressed A549 cells. In contrast, the expression of
LDHA was obviously decreased in ENO1-suppressed
SPCA-1 cells. To further confirm our results, we examined
the level of lactate production in ENO1-overexpressed
A549 cells and ENO1-suppressed SPCA-1 cells. Consistent
with the results of the Western blot, ENO1-overexpressed
A549 cells produced a more amount of lactate com-
pared to its control cells and untreated cells. Con-
versely, the production of lactate was significantly less
in ENO1-suppressed SPCA-1 cells than in its control
cells and untreated cells, suggesting the involvement of
ENO1 in inducing the glycolysis of NSCLC (Figure 2D).
ENO1 promotes cell proliferation, clone formation in vitro,
and tumorigenicity in vivo
Next we assessed the effect of ENO1 expression on A549
cell growth in vitro. The growth curves determined by 3-
(4, 5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium brom-
ide (MTT) assays showed that overexpressed ENO1
significantly elevated cell viability compared to its control
cells and untreated cells. MTT assays also showed that
transiently suppressed ENO1 significantly decreased cell
viability in A549 cells (Figure 3A). Colony formation as-
says showed that overexpressed ENO1 significantly in-
creased cell proliferation compared to its control cells and
untreated cells (Figure 3C). On the contrary, suppressed
ENO1 expression in SPCA-1 cells significantly inhibited
cell viability (Figure 3B) and clone formation (Figure 3D).
To confirm the growth effect of ENO1 in vivo, we per-
formed an in vivo tumorigenesis study by inoculating
A549 with or without ENO1 overexpression and SPCA-1
cells with or without ENO1 knockdown into nude mice.
Mice were sacrificed 15 days after inoculation, with
average tumor weights of 0.059 ± 0.016 vs 0.73 ± 0.12 g
in PLV-Ctr vs A549-ENO1 group and 0.95 ± 0.13 vs
0.435 ± 0.051 g in PLV-shCtr vs shENO1-B group, re-
spectively (P < 0.01) (Figure 3E). These results suggest
that ENO1 significantly promotes cell growth in vitro
and in vivo.
ENO1 promotes cell migration and invasion
To examine the effect of ENO1 on cell migration and
invasion, a transwell apparatus and Boyden chamber
coated with Matrigel were used. After 10-h incubation,
an elevated number of migrated cells were observed in
A549-ENO1 compared to its control cells and untreated
cells (P < 0.01) (Figure 4A). On the contrary, stably sup-
pressed ENO1 expression in SPCA-1 cells inhibited cell
migration and invasion in both shENO1-B and shENO1-
C cell groups compared to their respective control cells
and untreated cells (P < 0.01) (Figure 4C). Furthermore,
similar results were also observed in siRNA-mediated
suppression of ENO1 in NSCLC cells (Figure 4B, D). To
further assess the effect of ENO1 on NSCLC metastasis
Figure 2 The levels of ENO1 and glycolysis in ENO1-overexpressed and ENO1-suppressed NSCLC cells. (A) Stably upregulated ENO1 by
full-length ENO1 increased the expression of ENO1 in A549 cells by qRT-PCR and Western blotting. (B) Stably knocking down ENO1 by shRNA
reduced the expression of ENO1 in SPCA-1 cells by qRT-PCR and Western blotting. (C) Transiently knocking down ENO1 by siRNA reduced the
expression of ENO1 by qRT-PCR and Western blotting. (D) Western blotting showing the protein expression level of LDHA in ENO1-overexpressed
A549 cells and ENO1-suppressed SPCA-1 cells. The histograms showed the relative levels of lactate in NSCLC with ENO1 overexpression and
silencing. All of the experiments were repeated at least three times. β-Actin served as a loading control. Bars show the mean ± SD; (*P < 0.05).
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SPCA-1 cells, and their control cells were independently
injected into the spleens of nude mice. Fluorescence im-
ages showed that a large amount of intra-liver metastasis
nodules was generated in the mice injected with A549-
ENO1 cells, while a few small clusters were observed in
A549 PLV-Ctr cells. In addition, a few small nodules
were observed in SPCA-1 shENO1-B cells, while a var-
iety of large clusters were observed in SPCA-1 PLV-
shCtr cells. These are consistent with the hematoxylin
and eosin (H&E)-stained liver sections (Figure 4E). Similar
to the results in vitro, ENO1 promotes the metastasis of
NSCLC cells.
ENO1 regulates the expression of cell cycle and
EMT-associated genes in NSCLC
To further study the mechanism by which ENO1 regu-
lates cell proliferation, migration, and invasion, the pro-
tein levels of cell cycle and EMT-associated genes wereexamined in A549 and SPCA-1 cells with stably overex-
pressed or suppressed ENO1. In ENO1 stably overex-
pressing A549 cells, activation of p-Rb (ser 780) was
increased as well as the elevated expression of cyclin D1,
cyclin E1, and c-Myc. In contrast, the expression of p21
was inhibited. Stably knocking down endogenous ENO1
expression in SPCA-1 inhibited the activation of p-Rb
(ser 780), and the expression of cyclin D1, cyclin E1, and
c-Myc were decreased, while levels of p21 were upregu-
lated (Figure 5A). We also found that upregulated ENO1
expression elevated the expression of EMT marker genes
including snail, vimentin, and N-cadherin, yet inhibited
E-cadherin in A549 cells. Conversely, downregulated
ENO1 expression in SPCA-1 cells inhibited the expres-
sion of these proteins and elevated E-cadherin expres-
sion (Figure 5B). Similar changes in cell cycle regulators
cyclin D1 and p21 as well as EMT-associated genes in-
cluding E-cadherin, N-cadherin, and vimentin were ob-
served in tumor tissues by IHC (Figure 6A, B). However,
Figure 3 (See legend on next page.)
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Figure 3 ENO1 promotes cell proliferation in vitro and tumorigenicity in vivo. (A) In vitro viability of A549 cell was increased in ENO1-
overexpressed cells and was reduced in ENO1-suppressed cells compared to control cells by MTT assay. (B) In vitro viability of SPCA-1 cell was
decreased in ENO1-suppressed cells compared to control cells by MTT assay. (C) In vitro proliferative ability of A549 cells was significantly increased in
ENO1-overexpressed cells compared to control cells by clone formation assay. (D) In vitro proliferative ability of SPCA-1 cells was significantly decreased
in ENO1-suppressed cells compared to control cells by clone formation assay. (E) In vivo tumorigenicity of A549 cells in nude mice was
significantly increased in ENO1-overexpressed cells compared to PLV-Ctr cells. In vivo tumorigenicity of SPCA-1 cells in nude mice was significantly
decreased in ENO1-suppressed cells compared to PLV-shCtr cells (N = 6 per group). One-way ANOVA was used for MTT assay and plate clone
formation. Data are presented as mean ± SD for three independent experiments (*P < 0.05).
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duce any epithelial to mesenchymal morphology transi-
tion changes in A549 or SPCA-1 cells (Additional file 1:
Figure S1).ENO1 regulates FAK-mediated PI3K/AKT pathway to
promote cell glycolysis, proliferation, migration,
and invasion
PI3K/AKT has been reported to be a key signal pathway
promoting cell proliferation and EMT and can be modu-
lated by FAK [18]. We found that overexpression of ENO1
significantly increased levels of β-catenin and phosphory-
lated FAK, PI3K, and AKT, but not their total protein
levels (Figure 5C). Suppression of ENO1 had the opposite
effect on the FAK/PI3K/AKT pathway. To further study
the mechanism by which ENO1 regulates cell glycolysis,
proliferation, migration, and invasion, ENO1-suppressed
SPCA-1 cells were treated with human angiotensin II (Ang
II) to induce the phosphorylation of FAK [19]. Ang II treat-
ment reversed the effects of ENO1 knockdown on cell
glycolysis, viability, migration, and invasion (Figure 7A–C).
We observed a consistent effect on the FAK/PI3K/AKT
pathway after Ang II treatment of ENO1-suppressed
SPCA-1 cells whereby levels of p-AKT, LDHA, cyclin D1,
c-Myc, p21, and β-catenin were restored (Figure 5D).
These results implied that ENO1 is an upstream signal fac-
tor modulating the FAK/PI3K/AKT pathway in NSCLC,
and ENO1 regulates FAK/PI3K/AKT pathway to promote
cell glycolysis, proliferation, migration, and invasion.Discussion
Upregulated expression of ENO1 has been detected in
several cancers, such as glioblastoma [20], head and neck
cancer [21], pancreatic cancer [22], and prostate cancer
[23]. However, the role of ENO1 in NSCLC is still contro-
versial [13-16], which needs to be further identified. In this
study, we confirmed that the expression of ENO1 mRNA
and protein was frequently overexpressed in NSCLC tis-
sues compared to non-cancerous lung tissues as well as in
NSCLC cells compared to HBE cells. These results are
consistent with Chang et al.’s report supporting an onco-
genic role for ENO1 in NSCLC [13], but not Chang’s
study [15].In order to evaluate the function of ENO1 and eliminate
the influence of MBP-1 on NSCLC, we firstly performed
an immunofluorescence and observed that ENO1 was
expressed in the cytoplasm but not in the nucleus (MBP-1)
in A549 and SPCA-1 cells. Furthermore, we also found
that MBP-1 was not expressed by Western blot assay in
A549 and SPCA-1 cells. The abovementioned results
suggested that both two cells could be used as well-
defined models to evaluate the function of ENO1 on
NSCLC. Further, stable ENO1-overexpressed A549 cells
and stable ENO1-suppressed SPCA-1 cells as well as tran-
sient ENO1-suppressed A549 and SPCA-1 cells were re-
spectively constructed, which was used to investigate the
role of ENO1 in NSCLC.
ENO1 was originally described as an enzyme responsible
for the glycolytic pathway. To further assess the effect of
ENO1 on NSCLC cells, we analyzed the glycolysis changes
triggered by ENO1 and found that overexpressed and sup-
pressed ENO1 respectively increased and decreased the
production of lactate. These data suggested that ENO1
was involved in inducing glycolysis in NSCLC.
Previous studies have demonstrated that ENO1 overex-
pression was positively associated with progression and
poor prognosis in neuroendocrine tumors, neuroblast-
oma, pancreatic cancer, prostate cancer, cholangiocarci-
noma, thyroid carcinoma, hepatocellular carcinoma, and
breast cancer [14,21-27]. Further, ENO1 has been shown
to promote cell proliferation, cycle progression, migration,
and invasion [14,21-33], which suggests that ENO1 func-
tions as an oncogene in tumor pathogenesis. In this study,
we found that overexpressed ENO1 significantly elevated
cell proliferation and clone formation in vitro as well as
tumorigenesis in vivo. Furthermore, we also observed that
overexpressed ENO1 induced cell migration, invasion, and
metastasis in NSCLC. Our results are consistent with
previous reports in other tumors that ENO1 functions
as an oncogene [13,14,29,34] but are in contrast with
Zhou et al.’s report that ENO1 overexpression suppressed
EMT in NSCLC A549 cell line [16].
The biological functions of ENO1 found in this study
provide a mechanistic basis for the pathological and clin-
ical observations. When we examined the key regulators
of the glycolysis and cell cycle at the G1-S phase transi-
tion, we discovered that suppression of ENO1 inhibited
Figure 4 ENO1 promotes cell migration and invasion. (A) Stably upregulated ENO1 elevated the migration and invasion of A549 cells in vitro.
(B) Transiently knocking down ENO1 reduced the migration and invasion of A549 cells in vitro. (C, D) Stable and transient downregulated ENO1
reduced the migration and invasion of SPCA-1 cells in vitro. (E) External optical fluorescence images of liver were obtained 40 days after spleen
injection. Representative photographs of H&E staining of metastatic cancer tissues (M) are shown. Data are presented as mean ± SD for three
independent experiments (*P < 0.05).
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Figure 5 ENO1 regulates the expression of cell cycle and EMT-associated genes via FAK/PI3K/AKT pathway in NSCLC cells. (A) In A549
cells, overexpressed ENO1 increased the levels of p-Rb (ser 780) and oncogenic cell cycle regulators cyclin D1, cyclin E1, and c-Myc and decreased
the expression of tumor suppressor p21. Conversely, downregulated ENO1 expression in SPCA-1 cells inhibited the expression of these proteins in
addition to p21. (B) In A549 cells, overexpressing ENO1 increased the expression of EMT-marker genes including snail, vimentin, and N-cadherin
and decreased the expression of E-cadherin. In SPCA-1 cells, suppressing ENO1 expression decreased the expression of these proteins in addition
to E-cadherin. (C) In A549 cells, upregulated ENO1 increased levels of β-catenin, phos-FAK, PI3K, and AKT, but not their total protein levels; in SPCA-1
cells, reduced ENO1 expression reduced the levels of β-catenin, phos-FAK, PI3K, and AKT, but not their total protein levels. (D) ENO1-suppressed
SPCA-1 cells were treated with Ang II (1 μmol/l) for 12 h to activate the phosphorylation of FAK, then cellular p-FAK, p-AKT, LDHA, cyclin D1, c-Myc,
p21, and β-catenin were assessed by Western blot. β-Actin served as a loading control. All of the experiments were repeated at least three times.
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cyclin E1 while elevating the expression of p21, which
promoted cell glycolysis and proliferation of NSCLC.
EMT is regarded as a key event in tumor migration and
invasion progression. In this study, we further examined
the expression of EMT marker genes and found that
knocking down ENO1 expression induced the protein
levels of E-cadherin while suppressing the expression of
snail, vimentin, and N-cadherin in NSCLC cells. These
results are consistent with our previous report of ENO1
in glioma [17]. However, ENO1 overexpression did not
lead to any changes from epithelial to mesenchymal tran-
sition in NSCLC cells.
PI3K/AKT is a key signal mediator during carcinogen-
esis [35,36], and its activation induces glycolysis [37-39]
and c-Myc-mediated cell cycle transition [40] and pro-
motes the progression of EMT [37,41]. In addition, c-Myc
has also been shown to regulate energy metabolism by
regulating LDHA in tumor [42]. We hypothesized thatoncogenic ENO1 functions through the PI3K/AKT path-
way in NSCLC. We found that suppressed ENO1 signifi-
cantly decreased the protein levels of β-catenin and
phosphorylated PI3K and AKT, but not their total pro-
tein levels in SPCA-1 cells, which is similar to our previ-
ous report in glioma [17]. Interestingly, we examined
the protein levels of FAK, an upstream signal factor of
the PI3K/AKT pathway, and found that suppressed
ENO1 significantly decreased levels of phosphorylated
FAK, but not its total protein levels. We speculated that
ENO1 regulates cell glycolysis, proliferation, migration,
and invasion through FAK-mediated PI3K/AKT path-
way in NSCLC. To further clarify the specific mechan-
ism, Ang II, an activating agent of phosphorylated FAK
[19], was used to treat ENO1-suppressed SPCA-1 cells.
We observed that not only the production of lactate,
cell viability, migration, and invasion was restored but
also the expression levels of p-FAK, p-AKT, LDHA, cyc-
lin D1, c-Myc, p21, and β-catenin were rescued. These
Figure 6 ENO1 regulates the expression of cell cycle and EMT-associated genes of NSCLC cells. Immunohistochemical (IHC) staining of
ENO1, β-catenin, cyclin D1, p21 (A), and EMT-associated genes (B) including E-cadherin, N-cadherin, and vimentin in subcutaneous tumors of
mice injected with PLV-Ctr vs A549-ENO1, PLV-shCtr vs shENO1-B SPCA-1 cells.
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cell glycolysis, proliferation, migration, and invasion by
inactivating FAK-mediated PI3K/AKT pathway in NSCLC.
Thus, ENO1 may be a potential therapeutic target for
NSCLC treatment. Furthermore, nanotechnology has pro-
vided a good platform for cancer targeted therapy based
on nanoparticle unique properties. Therefore, we wish to
develop a nanoparticle formulation modified with tumor-
targeting single-chain antibody fragment (scFv) for sys-
temic delivery of siRNA-ENO1 in the future [43], which
may make it possible that ENO1 serves as a molecular
therapeutic target for NSCLC treatment.
Conclusions
In summary, ENO1 is overexpressed in NSCLC, promot-
ing cell glycolysis, proliferation, migration, invasion, and
tumorigenesis by activating the FAK-mediated PI3K/AKT
pathway and further modulating their downstream signal
molecules. To our knowledge, this is the first report of themolecular mechanisms of ENO1 in NSCLC and even
more in-depth than our previous report of ENO1 in gli-
oma [17]. Our study demonstrates that ENO1 may be a
potential therapeutic target for NSCLC treatment.
Materials and methods
Cell culture and sample collection
A549 line was obtained from ATCC Bioresource Center,
and SPCA-1 and HBE were purchased from Chinese
Academy of Sciences Cell Bank (Shanghai, China). A549
cells were cultured in Dulbecco’s modified Eagle’s medium
(DMEM, HyClone, Logan, UT) supplemented with 10%
fetal bovine serum (FBS) (ExCell, Shanghai, China); SPCA-
1 was cultured in RPMI 1640 medium (HyClone, Logan,
UT) supplemented with 10% FBS (ExCell, Shanghai,
China). HBE, an immortalized human bronchial epithe-
lial cell line, was grown in DMEM (HyClone, Logan,
UT) supplemented with 20% FBS (ExCell, Shanghai,
China). All cell lines were maintained in a humidified
Figure 7 Ang II treatment reverses the inhibitory effect of stably downregulated ENO1 in SPCA-1 cells. ENO1-suppressed SPCA-1 cells
were treated with Ang II (1 μmol/l) for 12 h to activate the phosphorylation of FAK, and cell viability, migration, and invasion were examined by
MTT assay, transwell apparatus, and Boyden chamber, respectively. (A) The inhibiting effect of stably downregulated ENO1 in glycolysis was
reversed by Ang II treatment. (B) The inhibiting effect of stably downregulated ENO1 in cell proliferation was reversed by Ang II treatment.
(C) The inhibiting effect of stably downregulated ENO1 in cell migration and invasion was reversed by Ang II treatment. Data are presented as
mean ± SD for three independent experiments (*P < 0.05).
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resected fresh primary NSCLC tissues and paired para-
cancer lung tissues as well as non-cancerous lung tissues
(5 cm away from tumor edge), 55 paraffin-embedded
primary NSCLC specimens, and 17 paraffin-embedded
non-cancerous lung specimens were obtained from the
Third Affiliated Hospital of Kunming Medical University
(Yunnan, China). Patients with a diagnosis of relapse and
who had received preoperative radiation, chemotherapy,
or biotherapy were excluded from the study to avoid any
changes in tumor marker determination due to the effect
of the treatment. The clinical processes were approved by
the Ethics Committees of the Third Affiliated Hospital of
Kunming Medical University, and patients provided in-
formed consent. Demographic and clinical data were ob-
tained from the patients’ medical records.
RNA isolation, RT-PCR, qRT-PCR, and primers
Total RNA was extracted from the cell lines and lung
tissues using Trizol (Takara, Shiga, Japan). RNA (1 μg)
was reverse transcribed into cDNA, and cDNA was
used as a template to amplify with specific primers for
sense: 5′-TCAATGGCGGTTCTCATGCT-3′ and for
antisense: 5′-GCAGCTCCAGGCCTTCTTTA-3′. ARF5
was used as an internal control with primers for sense: 5′-
ATCTGTTTCACAGTCTGGGACG-3′ and for antisense:
5′-CCTGCTTGTTGGCAAATACC-3′. Experiments wereperformed according to the manufacturer’s instructions
(Takara, Shiga, Japan). PCR conditions were 95°C for
10 min to activate DNA polymerase, followed by 45 cy-
cles of 95°C for 15 s, 60°C for 15 s, and 72°C for 15 s.
Specificity of amplification products was determined by
melting curve analysis. The qRT-PCR reactions for each
sample were repeated three times. Independent experi-
ments were done in triplicate.
Immunohistochemistry and evaluation of staining
Immunohistochemistry was performed in primary NSCLC
tissues, non-cancerous lung tissues, and mouse tumors
according to a previous description [44] with rabbit
polyclonal anti-ENO1 antibody (1:150; Proteintech, USA),
anti-cyclin D1, p21 antibody (1:100; Epitomics, Burlingame,
USA), β-catenin, N-cadherin, or E-cadherin antibody
(1:100; Cell Signaling Technology, Danvers, USA).
Stained tissue sections were reviewed and scored inde-
pendently by two investigators blinded to the clinical
data. For cytoplasmic staining, the score was based on
the sum of cytoplasm staining intensity and the percent-
age of stained cells. The staining intensity was scored as
previously described (0–3) [44,45], and the percentage of
positive staining areas of cells was defined as a scale of
0–3 (0: <10%, 1: 10%–25%, 2: 26%–75%, and 3: >76%). For
nuclear staining, the staining score was defined based on
the sum of nuclear staining intensity and the percentage
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scores were defined as follows: 0: <20%, 1: 20%–49%, 2:
50%–79%, and 3: >80%. The sum of the staining intensity
and staining extent scores (0–6) was used as the final
staining score. For statistical analysis, a final staining
score of 0 ~ 2 and 3 ~ 6 in cytoplasm or 0 ~ 3 and 4 ~ 6
in nucleus were respectively considered to be negative
and positive expression levels. Expression of ENO1 in
the nucleus was observed, but since ENO1 localizes in
cytoplasm, only the cytoplasmic staining was evaluated.
Immunofluorescence
Immunofluorescence was performed according to a pre-
vious study [46]. NSCLC cells were seeded on coverslips
in six-well plate and cultured overnight. Subsequently,
cells were fixed in 3.5% paraformaldehyde and perme-
abilized in KB solution and 0.2% Triton X-100 at room
temperature. After the blocking solution was washed out,
cells were incubated with a primary antibody (ENO1)
(diluted in KB) for 30–45 min at 37°C and subsequently
washed with KB twice. After incubating for 30–45 min at
37°C with secondary antibody (diluted in KB) and washing
with KB again, the coverslips were then mounted onto
slides with mounting solution containing 0.2 mg/ml DAPI
and sealed with nail polish. Slides were stored in a dark
box and observed under a fluorescent microscope.
Western blot analysis, reagent, and antibodies
Western blotting was performed as described [47] with
rabbit polyclonal anti-ENO1, LDHA antibody (1:1,000;
Proteintech, USA), anti-cyclin D1, p21, cyclin E1, C-Myc
antibody (1:1,000; Epitomics, Burlingame, USA), anti-
CDK4 antibody (1:400; Santa Cruz Biotechnology, Santa
Cruz, USA), anti-pRb (Ser780), FAK, p-FAK (Tyr397),
AKT, p-AKT (Ser473), PI3K, p-PI3K (Tyr458), snail, β-
catenin, N-cadherin, vimentin, and E-cadherin antibody
(1:1,000; Cell Signaling Technology, Danvers, USA). An
HRP-conjugated anti-rabbit IgG antibody was used as
the secondary antibody (Zhongshan, Beijing, China). Sig-
nals were detected using enhanced chemiluminescence re-
agents (Pierce, Rockford, IL). Ang II was purchased from
the Santa Cruz Biotechnology (Santa Cruz, USA).
Transfection and infection
The full-length ENO1-GFP (ENO1), GFP empty vector
(PLV-Ctr) lentiviruses were designed by Shanghai Gene-
chem (Genechem, Shanghai, China). The preparation of
lentiviruses expressing human ENO1 short hairpin RNA
(shENO1-A, B, C) (Table 2) was performed using the
pLVTHM-GFP lentiviral RNAi expression system [40].
NSCLC cell line A549 was infected with full-length ENO1-
GFP or GFP empty vector lentiviruses. SPCA-1 cells were
infected with shENO1-A, B, C or PLV-shCtr lentiviruses,
and polyclonal cells with GFP signals were selected forfurther experiments using FACS flow cytometry. Total
RNA was isolated, and levels of ENO1 mRNA were mea-
sured using real-time PCR analysis.
Transient transfection with siRNAs
siRNA for ENO1 was designed and synthesized by
Guangzhou RiboBio (RiboBio Inc, China). The sequence
of siENO1 is sense: 5′-GCAUUGGAGCAGAGGUUUA
dTdT-3′ and anti-sense: 3′-dTdTCGUAACCUCGUCU
CCAAAU-5′. The sequence of si-negative control (si-
Ctr) was also designed by RiboBio (RiboBio Inc, China).
Twenty-four hours prior to transfection, NSCLC cells
A549 and SPCA-1 were plated onto a 6-well plate or a
96-well plate (Nest Biotech, China) at 30%–50% conflu-
ence. They were then transfected into cells using Turbo-
Fect TM siRNATransfection Reagent (Fermentas, Vilnius,
Lithuania) according to the manufacturer’s protocol. Cells
were collected after 48–72 h for further experiments.
Metabolic profiling
Metabolic profiles were obtained to assess the relative
distribution of various cellular metabolites of NSCLC cells.
Cells were collected and quickly frozen. Further sample
preparation, metabolic profiling, peak identification, and
curation were performed by Metabolon (Durham, NC,
USA) using their described methods [48].
MTT assay
The viability of cell proliferation was assessed using MTT
assay according to our previous study [46]. Cells were
seeded in 96-well plates at a density of 1,000 cells/well.
Every 24 h for 7 days, 20 μl of MTT (5 mg/ml) (Sigma-
Aldrich, St. Louis, MO) was added to each well and in-
cubated for 4 h. Supernatants were removed, and 150 μl
of dimethyl sulfoxide (DMSO) (Sigma-Aldrich, St. Louis,
MO) was added to each well. The absorbance value (OD)
of each well was measured at 490 nm. For each experi-
mental condition, five parallel wells were assigned to each
group. Experiments were performed thrice.
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Clone formation assay was performed according to our
previous study [46]. Cells were seeded in 6-well culture
plates at 100 cells/well. Each cell group had three paral-
lel wells. After incubation for 14 days at 37°C, cells were
washed twice with Hank’s solution and stained with
hematoxylin solution. The number of colonies contain-
ing ≥50 cells was counted under a microscope. The
clone formation efficiency was calculated as (number of
colonies/number of cells inoculated) × 100%.
Cell migration and invasion assays
In vitro cell migration and invasion assays were exam-
ined according to our previous study [46]. For cell mi-
gration assays, 1 × 105 cells in a 100-μl medium without
serum were seeded on a fibronectin-coated polycarbon-
ate membrane insert in a transwell apparatus (Corning,
USA). In the lower surface, 500 μl DMEM with 10% FBS
was added as chemoattractant. After the cells were incu-
bated for 10 h at 37°C in a 5% CO2 atmosphere, Giemsa-
stained cells adhering to the lower surface were counted
under a microscope in five predetermined fields (100×).
All assays were independently repeated at least thrice.
For cell invasion assays, the procedure was similar to
the cell migration assay, except that the transwell mem-
branes were pre-coated with 24 μg/ml Matrigel (R&D
Systems, USA).
In vivo tumorigenesis in nude mice
According to our previous study [17], a total of 1 × 106
logarithmically growing A549 cells transfected with full-
length ENO1 and PLV-Ctr vector, SPCA-1 cells trans-
fected with shENO1-B, and the control PLV-shCtr vector
(N = 6 per group) in 0.1 ml Hank’s solution were subcuta-
neously inoculated into the left-right symmetric flank of
4–6-week-old male BALB/c-nu/nu mice. The mice were
maintained in a barrier facility on HEPA-filtered racks and
fed an autoclaved laboratory rodent diet. All animal
studies were conducted in accordance with the princi-
ples and procedures outlined in the National Institutes
of Health Guide for the Care and Use of Animals under
assurance number A3873-1. After 15 days, the mice were
sacrificed, and their tumors were excised, weighed, and
processed for histology.
In vivo metastasis assays
In vivo metastasis assays were performed according to a
previous study [46]. A total of 5 × 106 cells were injected
into nude mice (n = 5 for each group) through the spleen,
respectively. The optical fluorescence images were visual-
ized to monitor primary tumor growth and formation of
metastatic lesions. Forty days later, all mice were killed, in-
dividual organs were removed, and metastatic tissues were
analyzed by H&E staining.Statistical analysis
All data were independently repeated at least thrice.
SPSS 13.0 and Graph Pad Prism 5.0 software were used
for statistical analysis. One-way ANOVA or two-tailed
Student’s t-test were applied to determine the differences
between group in vitro analyses. The chi-squared test was
used to determine the differences of ENO1 protein ex-
pression between NSCLC tissues and non-cancerous lung
tissues of the lung. A p value of less than 0.05 was consid-
ered statistically significant.
Additional file
Additional file 1: Figure S1. Stably upregulated ENO1 (A) or
downregulated ENO1 (B) did not induce obvious epithelial to
mesenchymal morphology transition changes in SPCA-1 or A549 cells.
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